Stock Analiz

ORKA vs LNTH stock comparison

Oruka Therapeutics vs. Lantheus · data as of November 13, 2026

Oruka Therapeutics (ORKA) has a market value of about $7.1B, Lantheus (LNTH) about $6.6B.

On our five checks Lantheus scores higher: 2.6 out of 5 (average) against 0.4 (weak).

By area, the stronger company is Lantheus on value; Lantheus on future growth; Lantheus on track record; Lantheus on financial health; Lantheus on shareholder returns.

Oruka Therapeutics leads on 1 of the compared lines and Lantheus on 10.

Side by side

ORKALNTH
Size and price
Market cap$7.1B$6.6B
Share price$105.35$101.59
Score
Overall score (of 5)0.42.6
Value01
Future growth03
Track record02
Financial health25
Shareholder returns02
Valuation
P/E (TTM)—25.1
Forward P/E—16.0
Price / free cash flow—16.9
Price / sales—4.3
EV / EBITDA—17.2
PEG——
DCF value vs. price—−35%
Business
Revenue—$1.6B
Net income-$105M$270M
Free cash flow-$88M$393M
Net margin—17.3%
Gross margin (5-yr avg.)—57.3%
ROIC (5-yr avg.)-22.8%9.4%
Growth
Revenue growth (1 yr)—0.5%
Revenue growth (5 yrs, per year)—35.4%
EPS growth (5 yrs, per year)——
Balance sheet and payouts
Net cash (cash minus debt)—$59M
Dividend yieldNoneNone
Shareholder yield0.0%4.5%
Analysts
Upside to average target+48%+4%
Consensus ratingStrong buyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: ORKA FY2025, LNTH TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Oruka Therapeutics or Lantheus?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Lantheus scores 2.6 out of 5 and Oruka Therapeutics 0.4; the table shows where each one is stronger.

Full Oruka Therapeutics analysis → Full Lantheus analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.